New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…
Celiac Disease in Pediatric Patients
A retrospective study shows that some patients presenting for pediatric rheumatology evaluation test positive for celiac disease—some without showing any gastrointestinal manifestations. Treatment includes a gluten-free diet…
Researchers Identify Molecule That Promotes Osteogenesis
New insights into bone cell biology—including the identification of parbendazole, a bone anabolic compound that promotes bone formation—may lead to better treatments for osteoporosis…
Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis
NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis. In the first study, online Sept. 21, Dr. Tamas Molnar…
FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz
(Reuters)—U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must be addressed in order…
60 Days to a Reciprocal Medical License in Nevada
A new law in Nevada streamlines medical licensure for physicians and could help rheumatologist recruitment efforts…
Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…
Transatlantic Divide: How U.S. Pays Three Times More for Drugs
LONDON (Reuters)—U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such…
Hospital Workers Often Transfer Germs When Removing Gloves, Gowns
(Reuters Health)—Fluorescent lotion and black light revealed that healthcare workers often contaminate their skin and clothing while removing their protective gear, researchers say. This contamination can spread germs and place the healthcare workers at risk for infection, the authors write in JAMA Internal Medicine. “It was surprising for the participants in the study to see…
Secukinumab Effective for Psoriatic Arthritis
A Phase 3 study found secukinumab may be an effective alternative to anti-TNF therapies for treating psoriatic arthritis, suggesting interleukin 17A may play a role in the disease…
- « Previous Page
- 1
- …
- 270
- 271
- 272
- 273
- 274
- …
- 309
- Next Page »